{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:15:38Z","timestamp":1790705738078,"version":"4.1.0"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202108070132"],"award-info":[{"award-number":["202108070132"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003990","name":"\u00cele-de-France Regional Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Retinal and Eye Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.preteyeres.2026.101443","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:48:12Z","timestamp":1769759292000},"page":"101443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Ocular gene therapy mediated by AAV vectors: an overview of immunosuppressive treatments and immunomonitoring of patients involved in clinical trials"],"prefix":"10.1016","volume":"111","author":[{"given":"Duohao","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle A.","family":"Chauveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Cabon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vendom\u00e8le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vignal-Clermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanadi","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Ail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-9321","authenticated-orcid":false,"given":"Deniz","family":"Dalkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Fisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.preteyeres.2026.101443_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-031-27681-1_18","article-title":"Preexisting neutralizing antibodies against different adeno-associated virus serotypes in humans and large animal models for gene therapy","volume":"1415","author":"Ail","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.omtm.2022.01.011","article-title":"Systemic and local immune responses to intraocular AAV vector administration in non-human Primates","volume":"24","author":"Ail","year":"2022","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2026.101443_bib6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/hmg\/5.5.591","article-title":"Gene transfer into the mouse retina mediated by an adeno-associated viral vector","volume":"5","author":"Ali","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.preteyeres.2026.101443_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000659","article-title":"Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness","volume":"2","author":"Amado","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICU.0000000000000657","article-title":"Age-related macular degeneration therapy: a review","volume":"31","author":"Ammar","year":"2020","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/jop.2018.0087","article-title":"Gene therapy for inherited retinal degeneration","volume":"35","author":"Arbabi","year":"2019","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.preteyeres.2026.101443_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV vector toolkit: poised at the clinical crossroads","volume":"20","author":"Asokan","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib11","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.2337\/db09-1606","article-title":"TNF-\u03b1 signals through PKC\u03b6\/NF-\u03baB to alter the tight junction complex and increase retinal endothelial cell permeability","volume":"59","author":"Aveleira","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.preteyeres.2026.101443_bib12","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/sj.gt.3301990","article-title":"Stable rAAV-mediated transduction of rod and cone photoreceptors in the Canine retina","volume":"10","author":"Bainbridge","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib13","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber's congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib14","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on leber's congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib15","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002865","article-title":"AAV2 gene therapy readministration in three adults with congenital blindness","volume":"4","author":"Bennett","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.omtm.2023.08.015","article-title":"Modifying immune responses to adeno-associated virus vectors by capsid engineering","volume":"30","author":"Bentler","year":"2023","journal-title":"Mol. Ther., Methods Clin. Dev."},{"issue":"5 18","key":"10.1016\/j.preteyeres.2026.101443_bib19","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","article-title":"Necroptosis, pyroptosis and apoptosis: an intricate game of cell death","volume":"18","author":"Bertheloot","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/09273948.2016.1180401","article-title":"Molecular signals involved in human B cell migration into the retina: in vitro investigation of ICAM-1, VCAM-1, and CXCL13","volume":"25","author":"Bharadwaj","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2026.101443_bib21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/jca.22069","article-title":"Efficient removal of antibodies to adeno-associated viruses by immunoadsorption","volume":"38","author":"Boedecker-Lips","year":"2023","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.preteyeres.2026.101443_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01077","article-title":"Immunophenotyping reveals no significant perturbation to PBMC subsets when Co-cultured with colorectal adenocarcinoma Caco-2 cells exposed to X-Rays","volume":"11","author":"Borsci","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamaophthalmol.2018.6902","article-title":"Immune response and intraocular inflammation in patients with leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene: a secondary analysis of a phase 1\/2 clinical trial","volume":"137","author":"Bouquet","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2026.101443_bib323","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 gene therapy for duchenne muscular dystrophy using a translational optimized AAV vector","volume":"20","author":"Bowles","year":"2012","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.preteyeres.2026.101443_bib24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/gt.2016.31","article-title":"Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs","volume":"23","author":"Boyd","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.immuni.2019.05.012","article-title":"A call for Blood-In human immunology","volume":"50","author":"Brodin","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.preteyeres.2026.101443_bib26","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors - implications for treatment success and safety","author":"Bucher","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2026.101443_bib27","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/s41598-023-28830-7","article-title":"Extra-viral DNA in adeno-associated viral vector preparations induces TLR9-dependent innate immune responses in human plasmacytoid dendritic cells","volume":"13","author":"Bucher","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2026.101443_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2015.08.002","article-title":"Engineering the AAV capsid to optimize vector\u2013host-interactions","volume":"24","author":"B\u00fcning","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/545493","article-title":"Cytokines as biomarkers in rheumatoid arthritis","volume":"2014","author":"Burska","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.preteyeres.2026.101443_bib30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/hgtb.2018.038","article-title":"Assessment of humoral, innate, and T-Cell immune responses to adeno-associated virus vectors","volume":"29","author":"Calcedo","year":"2018","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.preteyeres.2026.101443_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40259-023-00629-y","article-title":"AAV-based strategies for treatment of retinal and choroidal vascular diseases: advances in age-related macular degeneration and diabetic retinopathy therapies","volume":"38","author":"Castro","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.preteyeres.2026.101443_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J. Pediatr."},{"key":"10.1016\/j.preteyeres.2026.101443_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omtm.2019.05.012","article-title":"Enhancement of adeno-associated virus-mediated gene therapy using hydroxychloroquine in murine and human tissues","volume":"14","author":"Chandler","year":"2019","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2026.101443_bib322","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cells13070624","article-title":"Role of the skin immune system in wound healing","volume":"13","author":"Cioce","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.preteyeres.2026.101443_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.01.028","article-title":"Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age","volume":"33","author":"Clare","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib40","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.molmed.2017.09.002","article-title":"Biomarker potential of extracellular miRNAs in Duchenne muscular dystrophy","volume":"23","author":"Coenen-Stass","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2017.02.018","article-title":"Gene therapy in neovascular age-related macular degeneration: three-year Follow-up of a phase 1 randomized dose escalation trial","volume":"177","author":"Constable","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.omtm.2023.06.001","article-title":"Adeno-associated virus-mediated gene therapy in a patient with canavan disease using dual routes of administration and immune modulation","volume":"30","author":"Corti","year":"2023","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2026.101443_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101323","article-title":"Multiple gene therapy as a tool for regulating the expression of molecules involved in neovascular age-related macular degeneration","volume":"104","author":"Corydon","year":"2025","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2026.101443_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00281-008-0106-7","article-title":"Mechanisms of leukocyte migration across the blood-retina barrier","volume":"30","author":"Crane","year":"2008","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib48","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to aav-mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib51","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/09273948.2018.1439069","article-title":"Immunopathology of virus-induced anterior uveitis","volume":"26","author":"De Groot-Mijnes","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2026.101443_bib52","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1089\/hum.2021.135","article-title":"Intracerebral gene therapy in four children with sanfilippo B syndrome: 5.5-year Follow-Up results","volume":"32","author":"Deiva","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib53","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.chembiol.2017.08.019","article-title":"Small-Molecule targets in immuno-oncology","volume":"24","author":"Dhanak","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib55","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression","volume":"129","author":"Ding","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.preteyeres.2026.101443_bib56","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1016\/j.ymthe.2025.03.003","article-title":"Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies","volume":"33","author":"Doshi","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/hum.2019.297","article-title":"Toxicity and efficacy evaluation of an Adeno-Associated virus vector expressing codon-optimized RPGR delivered by subretinal injection in a canine model of X-linked retinitis pigmentosa","volume":"31","author":"Dufour","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib59","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.aam7928","article-title":"Inflammation and metabolism in tissue repair and regeneration","volume":"356","author":"Eming","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.preteyeres.2026.101443_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.666666","article-title":"T cell-mediated immune responses to AAV and AAV vectors","volume":"12","author":"Ertl","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib64","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/gt.2014.61","article-title":"A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer","volume":"21","author":"Ferrand","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib65","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2013.169","article-title":"Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy","volume":"25","author":"Ferreira","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib66","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","article-title":"Gene therapy for leber hereditary optic neuropathy: initial results","volume":"123","author":"Feuer","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2026.101443_bib67","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.preteyeres.2026.101443_bib320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2022.08.009","article-title":"A first-in-human phase I\/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK. GALGT2","volume":"27","author":"Flanigan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2026.101443_bib70","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib71","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1097\/TP.0000000000001379","article-title":"Impact of immune-modulatory drugs on regulatory T cell","volume":"100","author":"Furukawa","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.preteyeres.2026.101443_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052719","article-title":"Ceramides as mediators of oxidative stress and inflammation in cardiometabolic disease","volume":"23","author":"Gaggini","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.preteyeres.2026.101443_bib73","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood.V97.12.3733","article-title":"Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX","volume":"97","author":"Ge","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.preteyeres.2026.101443_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121881","article-title":"Immunogenicity of novel AAV capsids for retinal gene therapy","volume":"11","author":"Gehrke","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.preteyeres.2026.101443_bib75","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1006\/meth.1996.0117","article-title":"Transgenic expression of IFN-\u03b3 in the eye as a model for studying ocular inflammatory disease","volume":"10","author":"Geiger","year":"1996","journal-title":"Methods"},{"key":"10.1016\/j.preteyeres.2026.101443_bib77","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib79","article-title":"RNA-based therapies in inherited retinal diseases","volume":"14","author":"Girach","year":"2022","journal-title":"Ther Adv. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.655478","article-title":"Cell-Mediated immunity to NAGLU transgene following intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome","volume":"12","author":"Gougeon","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib81","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.preteyeres.2026.101443_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125078","article-title":"Detection of innate immune response modulating impurities in therapeutic proteins","volume":"10","author":"Haile","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.preteyeres.2026.101443_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26830-7","article-title":"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models","volume":"12","author":"Hakim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.preteyeres.2026.101443_bib85","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3233\/JAD-160420","article-title":"Complement biomarkers as predictors of disease progression in alzheimer's disease","volume":"54","author":"Hakobyan","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.preteyeres.2026.101443_bib86","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/rcm.3947","article-title":"Elevated levels of hydroxylated phosphocholine lipids in the blood serum of breast cancer patients","volume":"23","author":"Hammad","year":"2009","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.preteyeres.2026.101443_bib87","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib88","volume":"vol. 6","author":"He","year":"2023"},{"key":"10.1016\/j.preteyeres.2026.101443_bib90","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1089\/hum.2022.216","article-title":"Neonatal Fc receptor inhibition enables adeno-associated virus gene therapy despite pre-existing humoral immunity","volume":"34","author":"Horiuchi","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib91","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"H\u00f6sel","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.preteyeres.2026.101443_bib92","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.devcel.2017.10.029","article-title":"Molecular anatomy of the developing human retina","volume":"43","author":"Hoshino","year":"2017","journal-title":"Dev. Cell"},{"key":"10.1016\/j.preteyeres.2026.101443_bib93","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/jnc.12662","article-title":"Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy","volume":"129","author":"Hu","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.preteyeres.2026.101443_bib94","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jaci.2022.09.037","article-title":"Cold exposure impairs extracellular vesicle swarm-mediated nasal antiviral immunity","volume":"151","author":"Huang","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib95","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/02713683.2013.779720","article-title":"Direct comparison of administration routes for AAV8-mediated ocular gene therapy","volume":"38","author":"Igarashi","year":"2013","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.preteyeres.2026.101443_bib96","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib98","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s10529-017-2417-z","article-title":"Potential plasma lipid biomarkers in early-stage breast cancer","volume":"39","author":"Jiang","year":"2017","journal-title":"Biotechnol. Lett."},{"issue":"5 13","key":"10.1016\/j.preteyeres.2026.101443_bib99","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","article-title":"TLR signaling","volume":"13","author":"Kawai","year":"2006","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.preteyeres.2026.101443_bib100","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1089\/hum.2018.144","article-title":"Dosage thresholds and influence of transgene cassette in adeno-associated virus-related toxicity","volume":"29","author":"Khabou","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib104","author":"Klein"},{"key":"10.1016\/j.preteyeres.2026.101443_bib318","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.preteyeres.2026.101443_bib105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/gt.2014.115","article-title":"Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human Primates","volume":"22","author":"Kotterman","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib106","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2023.194","article-title":"Complement system response to adeno-associated virus vector gene therapy","author":"Kropf","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib110","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2174\/0929867325666180904120029","article-title":"Lipids as biomarkers of cancer and bacterial infections","volume":"26","author":"Larrouy-Maumus","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.preteyeres.2026.101443_bib111","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ymthe.2017.09.014","article-title":"Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis","volume":"26","author":"Le Meur","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib112","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jgm.1126","article-title":"AAV serotypes for improved ocular gene transfer","volume":"10","author":"Lebherz","year":"2008","journal-title":"J. Gene Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib113","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib114","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.preteyeres.2026.101443_bib115","article-title":"A versatile toolkit for overcoming AAV immunity","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.107955","article-title":"Longitudinal evaluation of immediate inflammatory responses after intravitreal AAV2 injection in rats by optical coherence tomography","volume":"193","author":"Liu","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.preteyeres.2026.101443_bib119","article-title":"The clinical safety landscape for ocular AAV gene therapies: a systematic review and meta-analysis","volume":"28","author":"Liu","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.preteyeres.2026.101443_bib316","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1664968","article-title":"Immune responses in retinal gene therapy: challenges, mechanisms, and future strategies","volume":"16","author":"Ma","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib121","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2026.101443_bib123","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib125","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 MutationeAssociated inherited retinal dystrophy results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2026.101443_bib306","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing Anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2026.101443_bib127","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/157339511796196584","article-title":"Generation of regulatory T cells to antigen expressed in the retina","volume":"7","author":"McPherson","year":"2011","journal-title":"Curr. Immunol. Rev."},{"key":"10.1016\/j.preteyeres.2026.101443_bib129","first-page":"58","article-title":"Immunity to homologous grafted skin. III. The fate of skin homographs transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye","volume":"29","author":"Medawar","year":"1948","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib315","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib131","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne's muscular dystrophy","author":"Mendell","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib132","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib314","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.preteyeres.2026.101443_bib313","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.preteyeres.2026.101443_bib134","unstructured":"Michaelides, M., Besirli, C.G., Yang, Y., Chien Wong, S., Sahel, J., Mahmood Shah, S., Kumaran, N., Huckfeldt, R., Comander, J., Georgiadis, A., Naylor, S., Xu, J., Clark, M., Anglade, E., Wong, P., Fleck, P., Smith, A., Ripamonti, C., Ali, R., Forbes, A., Bainbridge, J., n.d. Ph1\/2 AAV5-RPGR (Botaretigene Sparoparvovec) Gene Therapy Trial in RPGR-associated X-linked Retinitis Pigmentosa (XLRP)."},{"key":"10.1016\/j.preteyeres.2026.101443_bib135","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.preteyeres.2026.101443_bib136","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/mt.2012.258","article-title":"Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors","volume":"21","author":"Mimuro","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib137","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib138","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/TP.0b013e3182590d8f","article-title":"In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function","volume":"94","author":"Miroux","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.preteyeres.2026.101443_bib139","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.ymthe.2021.02.013","article-title":"Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I\/IIa gene therapy trial","volume":"29","author":"Mishra","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib140","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.preteyeres.2026.101443_bib141","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14712598.2018.1389886","article-title":"Gene therapy for inherited retinal and optic nerve degenerations","volume":"18","author":"Moore","year":"2018","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib142","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jmv.21360","article-title":"Diverse IgG subclass responses to adeno-associated virus infection and vector administration","volume":"81","author":"Murphy","year":"2009","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib144","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib145","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib147","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ekir.2019.08.019","article-title":"Steroid-associated side effects in patients with primary proteinuric kidney disease","volume":"4","author":"Oh","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.preteyeres.2026.101443_bib307","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib312","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.preteyeres.2026.101443_bib150","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17269-x","article-title":"Plasmid-mediated gene transfer of Cas9 induces vector-related but not SpCas9-related immune responses in human retinal pigment epithelial cells","volume":"12","author":"Pfromm","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2026.101443_bib152","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.preteyeres.2026.101443_bib153","article-title":"AAV-Delivered CRISPR-Cas9 elicits persistent retinal immune responses compared with transient responses to RNP","volume":"12","author":"Pulman","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.preteyeres.2026.101443_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2025.101354","article-title":"Gene therapy-associated uveitis (GTAU): understanding and mitigating the adverse immune response in retinal gene therapy","volume":"106","author":"Purdy","year":"2025","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2026.101443_bib155","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68401-y","article-title":"Single-cell transcriptomic analysis of retinal immune regulation and blood-retinal barrier function during experimental autoimmune uveitis","volume":"14","author":"Quinn","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2026.101443_bib311","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5\u2013Factor VIII Gene Transfer in Severe Hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.preteyeres.2026.101443_bib160","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 can induce innate and adaptive immune response in the primate eye","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib162","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091973","article-title":"Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy","volume":"14","author":"Ren","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.preteyeres.2026.101443_bib163","article-title":"Inter-individual variability in immune response to AAV ocular gene delivery impedes immunomonitoring","volume":"2025","author":"Ren","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.preteyeres.2026.101443_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MOL.0000000000000909","article-title":"Lipidome and inflammation interplay: the role of diet in this relationship","volume":"35","author":"Rovayo","year":"2024","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib167","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.preteyeres.2026.101443_bib168","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.180229","article-title":"Quinolinic acid potentially links kidney injury to brain toxicity","volume":"10","author":"Saliba","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.preteyeres.2026.101443_bib310","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","volume":"33","author":"Servais","year":"2023","journal-title":"Neuromuscular Disorders"},{"key":"10.1016\/j.preteyeres.2026.101443_bib170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.preteyeres.2026.101443_bib171","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jtv.2019.09.002","article-title":"Pharmacological control of inflammation in wound healing","volume":"28","author":"Shukla","year":"2019","journal-title":"J. Tissue Viability"},{"key":"10.1016\/j.preteyeres.2026.101443_bib173","first-page":"5509","article-title":"Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood","author":"Smith","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib174","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.ymthe.2024.05.004","article-title":"Engineered IgM and IgG cleaving enzymes for mitigating antibody neutralization and complement activation in AAV gene transfer","volume":"32","author":"Smith","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib175","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.12.11.24","article-title":"Safety and efficacy of adeno-associated viral gene therapy in patients with retinal degeneration: a systematic review and meta-analysis","volume":"12","author":"Sobh","year":"2023","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib176","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010641","article-title":"Acute inflammation in tissue healing","volume":"24","author":"Soliman","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.preteyeres.2026.101443_bib177","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.it.2008.08.002","article-title":"Immune regulation and the eye","volume":"29","author":"Stein-Streilein","year":"2008","journal-title":"Trends Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib178","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/08830180212066","article-title":"Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy","volume":"21","author":"Stein-Streilein","year":"2002","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib271","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.915412","article-title":"Immunogenicity risk assessment of spontaneously occurring therapeutic monoclonal antibody aggregates","volume":"13","author":"Swanson","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib272","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/tvst.13.8.18","article-title":"Ocular and serum profiles of inflammatory molecules associated with retinitis pigmentosa","volume":"13","author":"Tao","year":"2024","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib273","author":"Tardieu"},{"key":"10.1016\/j.preteyeres.2026.101443_bib274","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib275","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s12026-017-8961-8","article-title":"The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis","volume":"65","author":"Tatomir","year":"2017","journal-title":"Immunol. Res."},{"issue":"6 41","key":"10.1016\/j.preteyeres.2026.101443_bib276","first-page":"773","article-title":"The expanding vistas of spatial transcriptomics","volume":"41","author":"Tian","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib277","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coi.2020.05.005","article-title":"Dissecting genetic determinants of variation in human immune responses","volume":"65","author":"Tong","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib278","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/brain\/awy128","article-title":"Eliciting inflammation enables successful rehabilitative training in chronic spinal cord injury","volume":"141","author":"Torres-Esp\u00edn","year":"2018","journal-title":"Brain"},{"issue":"6 15","key":"10.1016\/j.preteyeres.2026.101443_bib279","first-page":"439","article-title":"Corticosteroids and glaucoma risk","volume":"15","author":"Tripathi","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.preteyeres.2026.101443_bib280","doi-asserted-by":"crossref","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","article-title":"Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion","volume":"114","author":"Tse","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.preteyeres.2026.101443_bib281","article-title":"Characterization of gene therapy associated Uveitis following intravitreal adeno-associated virus injection in mice","volume":"62","author":"Tummala","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2026.101443_bib282","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1479-5876-10-122","article-title":"Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates","volume":"10","author":"Unzu","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib283","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002103","article-title":"Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey","volume":"3","author":"Vandenberghe","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2026.101443_bib284","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01686","article-title":"Cellular and molecular mechanisms of anterior chamber-associated immune deviation (ACAID): what we have learned from knockout mice","volume":"8","author":"Vendom\u00e8le","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00504","article-title":"Subretinal injection of HY peptides induces systemic antigen-specific inhibition of effector CD4+ and CD8+ T-cell responses","volume":"9","author":"Vendom\u00e8le","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib286","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1089\/hum.2023.191","article-title":"Peripheral cellular immune responses induced by subretinal Adeno-Associated virus gene transfer can be restrained by the subretinal-associated immune inhibition mechanism","volume":"35","author":"Vendom\u00e8le","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib288","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40259-021-00468-9","article-title":"Safety of intravitreal gene therapy for treatment of subjects with leber Hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: the REVEAL Study","volume":"35","author":"Vignal-Clermont","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.preteyeres.2026.101443_bib290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders","author":"Vrellaku","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib292","article-title":"Efficacy and safety of rAAV2-ND4 treatment for Leber's hereditary optic neuropathy","volume":"6","author":"Wan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2026.101443_bib294","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","article-title":"Results at 2 years after gene therapy for RPE65-Deficient leber congenital amaurosis and severe early-Childhood\u2013Onset retinal dystrophy","volume":"123","author":"Weleber","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2026.101443_bib295","first-page":"1823","article-title":"Analysis of immune deviation elicited by antigens injected into the subretinal space","volume":"39","author":"Wenkel","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2026.101443_bib296","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/brv.12718","article-title":"Humoral immune responses to AAV gene therapy in the ocular compartment","volume":"96","author":"Whitehead","year":"2021","journal-title":"Biol. Rev. Camb. Phil. Soc."},{"key":"10.1016\/j.preteyeres.2026.101443_bib297","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1089\/hum.2022.222","article-title":"The degree of adeno-associated virus-induced retinal inflammation varies based on serotype and route of delivery: intravitreal, subretinal, or suprachoroidal","volume":"34","author":"Wiley","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2026.101443_bib309","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.preteyeres.2026.101443_bib298","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","article-title":"Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy","volume":"10","author":"Yang","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.preteyeres.2026.101443_bib300","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41586-024-07130-8","article-title":"Compartmentalized ocular lymphatic system mediates eye\u2013brain immunity","volume":"628","author":"Yin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.preteyeres.2026.101443_bib301","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17469899.2020.1762488","article-title":"Glucocorticoid-induced ocular hypertension: origins and new approaches to minimize","volume":"15","author":"Yorio","year":"2020","journal-title":"Expet Rev. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib308","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged \u22654 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib303","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/cmi.2009.52","article-title":"Inhibitory receptors of the immune system: functions and therapeutic implications","volume":"6","author":"Zhang","year":"2009","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.preteyeres.2026.101443_bib304","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adenoassociated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.preteyeres.2026.101443_bib305","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-022-00967-4","article-title":"Inhibition of cGAS-STING by JQ1 alleviates oxidative stress-induced retina inflammation and degeneration","author":"Zou","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.preteyeres.2026.101443_bib317","doi-asserted-by":"crossref","unstructured":"Leavitt, A.D., Konkle, B.A., Stine, K.C., Visweshwar, N., Harrington, T.J., Giermasz, A., Arkin, S., Fang, A., Plonski, F., Yver, A., Ganne, F., Agathon, D., Resa, M. de los A., Tseng, L.J., Di Russo, G., Cockroft, B.M., Cao, L., Rupon, J., 2024. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study. Blood 143, 796\u2013806. https:\/\/doi.org\/10.1182\/blood.2022018971.","DOI":"10.1182\/blood.2022018971"},{"key":"10.1016\/j.preteyeres.2026.101443_bib319","doi-asserted-by":"crossref","unstructured":"Fong, S., Yates, B., Sihn, C.R., Mattis, A.N., Mitchell, N., Liu, S., Russell, C.B., Kim, B., Lawal, A., Rangarajan, S., Lester, W., Bunting, S., Pierce, G.F., Pasi, K.J., Wong, W.Y., 2022. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nature Medicine 2022 28:4 28, 789\u2013797. https:\/\/doi.org\/10.1038\/s41591-022-01751-0.","DOI":"10.1038\/s41591-022-01751-0"},{"key":"10.1016\/j.preteyeres.2026.101443_bib321","doi-asserted-by":"crossref","unstructured":"Drygalski, A. Von, Giermasz, A., Castaman, G., Key, N.S., Lattimore, S., Leebeek, F.W.G., Miesbach, W., Recht, M., Long, A., Gut, R., Sawyer, E.K., Pipe, S.W., 2019. Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 3, 3241\u20133247. https:\/\/doi.org\/10.1182\/bloodadvances.2019000811.","DOI":"10.1182\/bloodadvances.2019000811"}],"container-title":["Progress in Retinal and Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946226000091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946226000091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:44:16Z","timestamp":1777610656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1350946226000091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":178,"alternative-id":["S1350946226000091"],"URL":"https:\/\/doi.org\/10.1016\/j.preteyeres.2026.101443","relation":{},"ISSN":["1350-9462"],"issn-type":[{"value":"1350-9462","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular gene therapy mediated by AAV vectors: an overview of immunosuppressive treatments and immunomonitoring of patients involved in clinical trials","name":"articletitle","label":"Article Title"},{"value":"Progress in Retinal and Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.preteyeres.2026.101443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101443"}}